{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:13:36Z","timestamp":1794438816068,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015992","name":"St Luke's Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL 2011\\u20135336"],"award-info":[{"award-number":["UL 2011\\u20135336"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2016\\u201312376"],"award-info":[{"award-number":["2016\\u201312376"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.radonc.2026.111406","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:09:44Z","timestamp":1769818184000},"page":"111406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer \u2212 PORTEC-4a an international, randomised, phase 3 trial"],"prefix":"10.1016","volume":"217","author":[{"given":"Anne Sophie V.M.","family":"van den Heerik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-4753","authenticated-orcid":false,"given":"Nanda","family":"Horeweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-1380","authenticated-orcid":false,"given":"Marie A.D.","family":"Haverkort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-8767","authenticated-orcid":false,"given":"Nienke","family":"Kuijsters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike L.A.","family":"Koppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies E.","family":"Nowee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7975-9604","authenticated-orcid":false,"given":"Henrike","family":"Westerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Fr\u00fchauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeltsje S.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem M.","family":"Mens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannet C.","family":"Beukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Gillham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-580X","authenticated-orcid":false,"given":"Dorine S.J.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Vandecasteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-9802","authenticated-orcid":false,"given":"Moritz","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Kiderlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-4505","authenticated-orcid":false,"given":"Stephan","family":"Polterauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Staebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-4788","authenticated-orcid":false,"given":"Bastiaan G.","family":"Wortman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"De Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Verhoeven-Adema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi A.","family":"Nout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Putter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.H.B.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-4321","authenticated-orcid":false,"given":"Carien L.","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert B.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111406_b0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2026.111406_b0010","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111406_b0015","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2026.111406_b0020","unstructured":"Board WHOCoTE: WHO Classification of Tumours: Female Genital Tumours (ed 5th). Lyon, International Agency for Research on Cancer, 2020."},{"key":"10.1016\/j.radonc.2026.111406_b0025","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0035","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2023.34.e85","article-title":"FIGO staging of endometrial cancer: 2023","volume":"34","author":"Berek","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0040","article-title":"Molecular profile-based adjuvant treatment for women with (high)intermediate-risk endometrial cancer: results of the international, multicentre, randomised, phase 3 PORTEC-4a trial","author":"van den Heerik","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0045","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11136-015-1217-y","article-title":"QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30","volume":"25","author":"King","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2026.111406_b0050","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s11136-021-02767-8","article-title":"Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D","volume":"30","author":"Jansen","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2026.111406_b0055","unstructured":"Authority NH: Open Data - Zorgproduct, 2024."},{"key":"10.1016\/j.radonc.2026.111406_b0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2023.09.006","article-title":"Budget impact analysis of molecular subtype profiling in endometrial cancer","volume":"178","author":"Plotkin","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0065","unstructured":"Authority NH: Zorgproduct Viewer, 2024."},{"key":"10.1016\/j.radonc.2026.111406_b0070","unstructured":"Netherlands NHCI: Zorginstituut Nederland - Medicijnkosten, 2024."},{"key":"10.1016\/j.radonc.2026.111406_b0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jval.2021.08.003","article-title":"Varying willingness to pay based on severity of illness: impact on health technology assessment outcomes of inpatient and outpatient drug therapies in the Netherlands","volume":"25","author":"Schurer","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.radonc.2026.111406_b0080","unstructured":"Netherlands NHCI: Costing Manual: Methods and Reference Prices for Economic Evaluations in Healthcare, 2024."},{"key":"10.1016\/j.radonc.2026.111406_b0085","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jval.2011.01.004","article-title":"Deriving a preference-based measure for cancer using the EORTC QLQ-C30","volume":"14","author":"Rowen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.radonc.2026.111406_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO-24-01887","article-title":"Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy for newly diagnosed, high-risk endometrial cancer: results in mismatch repair-deficient tumors","volume":"43","author":"Slomovitz","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Van Gorp","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0100","unstructured":"Nederland Z: Pakketadvies sluisgeneesmiddel dostarlimab (Jemperli\u00ae) voor de behandeling van baarmoederkanker, in Nederland Z (ed). Diemen, 10 July 2024."},{"key":"10.1016\/j.radonc.2026.111406_b0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2021.10.071","article-title":"Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer","volume":"164","author":"Orellana","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2023.04.010","article-title":"Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer","volume":"173","author":"Orellana","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0115","doi-asserted-by":"crossref","unstructured":"Devereaux KA, Steiner DF, Ho C, et al: A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma. International Journal of Gynecological Pathology Publish Ahead of Print, 2021.","DOI":"10.1097\/PGP.0000000000000841"},{"key":"10.1016\/j.radonc.2026.111406_b0120","article-title":"QPOLE: a quick, simple, and cheap alternative for POLE sequencing in endometrial cancer by multiplex genotyping quantitative polymerase chain reaction","volume":"9","author":"Van den Heerik","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.radonc.2026.111406_b0125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00428-023-03636-0","article-title":"Validation of Modaplex POLE mutation assay in endometrial carcinoma","volume":"483","author":"Dorca","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.radonc.2026.111406_b0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.32074\/1591-951X-926","article-title":"Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs","volume":"116","author":"Santoro","year":"2024","journal-title":"Pathologica"},{"key":"10.1016\/j.radonc.2026.111406_b0135","doi-asserted-by":"crossref","unstructured":"de Biase D, Maloberti T, Corradini AG, et al: Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice. Front Med (Lausanne) 10:1146499, 2023.","DOI":"10.3389\/fmed.2023.1146499"},{"key":"10.1016\/j.radonc.2026.111406_b0140","unstructured":"Board WCoTE: WHO Classification of Female Genital Tumours. . Lyon, International Agency for Research on Cancer, 2020."},{"key":"10.1016\/j.radonc.2026.111406_b0145","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/ijgc-2024-005916","article-title":"Validation and clinical performance of a single test, DNA based endometrial cancer molecular classifier","volume":"34","author":"Jamieson","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.radonc.2026.111406_b0150","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2026.111406_b0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.radonc.2026.111406_b0160","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jval.2011.12.003","article-title":"Condition-specific preference-based measures: benefit or burden?","volume":"15","author":"Versteegh","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.radonc.2026.111406_b0165","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s10198-024-01670-6","article-title":"The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands","volume":"25","author":"Pilz","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.radonc.2026.111406_b0170","article-title":"The EORTC QLU-C10D distinguished better between cancer patients and the general population than PROPr and EQ-5D-5L in a cross-sectional study","volume":"177","author":"D\u00f6hmen","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.radonc.2026.111406_b0175","article-title":"Short-course adjuvant vaginal cuff brachytherapy in early endometrial cancer compared with standard of care (SAVE): a randomized clinical trial","volume":"1","author":"Suneja","year":"2024","journal-title":"JCO Oncology Advances"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:16:32Z","timestamp":1785917792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S0167814026000447"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111406","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer \u2212 PORTEC-4a an international, randomised, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111406"}}